Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
September 30, 2020 07:07 AM EDTUpdated October 1, 04:09 AM
Coronavirus

Covid-19 roundup: No­var­tis' Vas Narasimhan sees drugs as 'bridge' to vac­cines; Mod­er­na spot­lights el­der­ly re­spons­es in NE­JM

ENDPOINTS

No­var­tis may be stay­ing out of the vac­cine pack, but the Swiss phar­ma gi­ant in­sists that its drugs will still have a cru­cial role to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times